Efficacy and Safety of SGLT2 Inhibitor Ipragliflozin in with Type 1 Diabetes patients using FGM

Not Applicable

Recruiting

• Conditions: Type 1 diabetes

• Registration Number: JPRN-UMIN000035555
• Lead Sponsor: Minami Osaka Hospital Internal Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-02-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1.The patient with severe ketosis, diabetic comA or previous coma within six weeks before examination start 2.The patient who developed severe hypoglycemia (a diabetic coma or a previous coma and convulsionsneed the assistance of the third person) within six weeks before examination start 3.The patient with medically important renal disease such as a history of renal vascular occlusive disease, nephrectomy, kidney transplantations, etc 4.The patient with dysuria, anuria, oliguria or the symptom of the anuria 5.The patient whom urinary tract infection having subjective symptoms, a sexual organs infectious disease developed in within six weeks before examination start 6.The patient with a severe renal function disorder (eGFR <30mL/min/1.73m2 or serum creatinine level >= 2.0mg/dL) or the end-stage renal disease on dialysis 7.The patient with a proliferative retinopathy (however, patients symptoms are stable by implementing the photocoagulation, etc., can incorporate) 8.The patient complicated with serious digestive tract disturbance within two weeks before examination start or the patient who has an operation career of serious digestive tract disturbance 9.The patient with pregnancy or may be pregnant and the patient in nursing 10.The patient with severe infectious disease, serious injury and before and after operation 11.The patient who receives systemic administration of corticosteroids drugs 12.The patient with a serious liver function disorder more than 100 U/l of AST or ALT 13.The patient with a history of allergy to Ipragliflozin 14.The patient with the past of a malignant tumor or the malignant tumor at the moment 15.In addition, patients who test the attending physician has determined to be inappropriate as a subject

Study & Design

• Study Type: Interventional
• Study Design: Not specified